| ACAs | Anti-centromere autoantibodies |
| ACE | Angiotensin-converting enzyme |
| ANA | Antinuclear antibody |
| ATAs | Anti-topoisomerase I autoantibodies |
| CREST | Calcinosis, RP, esophageal dysmotility, sclerodactyly, and telangiectasia |
| CRP | C-reactive protein |
| DLCO | Diffusing capacity for carbon monoxide |
| EF | Ejection fraction |
| ESR | Erythrocyte sedimentation rate |
| FVC | Forced vital capacity |
| FEV1 | Forced expiratory volume in one second |
| GAVE | Gastric antral venous ectasia |
| GI | Gastro-intestinal tract |
| HRCT | High-resolution computed tomography |
| ICAP | International Consensus on ANA Patterns |
| IVIG | Intravenous immunoglobulin |
| IIF | Indirect immunofluorescence |
| IIM | Idiopathic inflammatory myopathy |
| ILD | Interstitial lung disease |
| MCTD | Mixed connective tissue disease |
| NSAIDs | Nonsteroidal anti-inflammatory drugs |
| PAP | Pulmonary arterial pressure |
| PFT | Pulmonary function test |
| PMAT | Particle multi-analyte technology |
| RNAP3 | Anti-RNA polymerase III |
| RP | Raynaud’s phenomenon |
| SSc | Systemic sclerosis |
| TLC | Total lung capacity |
| UCTD | Undifferentiated connective tissue disease |